Neurofibromatosis Type 1 Clinical Trial
Official title:
Genetic Variation and Risk of Pediatric Brain Cancers
This study will analyze DNA samples to determine associations between maternal and offspring genetic factors and pediatric brain tumor development in children with Neurofibromatosis Type 1. Participating families (mother, father, child) will be asked to complete a short questionnaire and provide DNA samples (either saliva or blood). The information gained from your participation may one day help doctors develop strategies to reduce brain tumor risk in individuals with NF1. Please note: there is no therapy associated with this study.
The prenatal period is a developmentally vulnerable time point during which environmental conditions, including nutrition, can have life-long impacts on health.1,2 This is particularly relevant to many childhood cancers that are thought to initiate during pregnancy.3 As a consequence, there has been intense interest in whether prenatal exposures can modulate childhood cancer risk.4-6 It is important to recognize that both maternal and offspring genetic factors including those in nutritional pathways may play an important role in pediatric cancer risk through their effect on the child's exposure to nutrients important in development during the prenatal period. The purpose of this research study is to evaluate whether there are any maternal or offspring genetic factors in the folate pathway that may contribute to the development of brain tumors in children with Neurofibromatosis Type 1 through analysis of DNA samples collected from families. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03190915 -
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
|
Phase 2 | |
| Completed |
NCT03326388 -
Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours
|
Phase 1/Phase 2 | |
| Completed |
NCT00026780 -
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
|
||
| Active, not recruiting |
NCT01362803 -
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01218139 -
Analysis of Peripheral Nerve Sheath Tumors (PNSTs) in Neurofibromatosis Type 1 (NF1) Patients
|
N/A | |
| Recruiting |
NCT05149469 -
Molecular Aspects of Preimplantation Genetic Diagnosis for NF1
|
||
| Not yet recruiting |
NCT02505412 -
Subtle Myocardial Deformation Abnormalities in Asymptomatic Nf-1 Patients
|
N/A | |
| Terminated |
NCT02256124 -
Effect of Lamotrigine on Cognition in NF1
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT01218152 -
Microarray CGH Analysis of Circulating Tumoral Plasma DNA in NF1 Patients With MPNSTs
|
N/A | |
| Recruiting |
NCT03975829 -
Pediatric Long-Term Follow-up and Rollover Study
|
Phase 4 | |
| Recruiting |
NCT05186870 -
Reliability of Functional Outcome Measures in Neurofibromatosis 1: Test- Retest
|
||
| Active, not recruiting |
NCT03231306 -
Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas
|
Phase 2 | |
| Withdrawn |
NCT03332030 -
Stem Cells in NF1 Patients With Tumors of the Central Nervous System
|
||
| Recruiting |
NCT02964884 -
Interventions for Reading Disabilities in NF1
|
Phase 2 | |
| Recruiting |
NCT05388370 -
PASS of Paediatric Patients Initiating Selumetinib
|
||
| Recruiting |
NCT02777775 -
Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.
|
||
| Completed |
NCT02944032 -
Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1
|
N/A | |
| Completed |
NCT01851135 -
Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1
|
N/A | |
| Completed |
NCT01410006 -
Neurofibromatosis Type 1 Patient Registry
|
N/A | |
| Active, not recruiting |
NCT00326872 -
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
|
Phase 2 |